Loading...

Haleon plc

HLNCFPNK
HealthcareDrug Manufacturers - Specialty & Generic
$5.64
$0.23(4.16%)

Haleon plc (HLNCF) Company Profile & Overview

Explore Haleon plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Haleon plc (HLNCF) Company Profile & Overview

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Brian James McNamara

Contact Information

44 1932 822000
Building 5, Weybridge, KT13 0NY

Company Facts

24,561 Employees
IPO DateJul 28, 2022
CountryGB
Actively Trading

Frequently Asked Questions